Metronomic chemotherapy for head-and-neck cancers in coronavirus disease 2019 pandemic

Abstract

Sir, By April 24, 2020, the new coronavirus disease 2019 (COVID-19) patients account for 2,718,699 cases with 190,654 deaths (https://www.worldometers.info/coronavirus). Cancer patients are at high risk for becoming seriously ill from COVID-19 infection because of the compromised immune status due to cancer as well as ongoing treatment involving chemotherapy, immunotherapy, and targeted therapy. Most of these patients (60%-70%) in developing nations present in locally advanced stages.[[2]] Curative treatment modalities for these cancers include a combination of surgery, radiation, and/or chemotherapy. [Extracted from the article]